Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcript inducer of AURKA lysosomal degradation (TIALD)
- Target
- TIALD
- Molecular classification
- Long non-coding RNA (lncRNA)
01
Overview
Transcript inducer of AURKA lysosomal degradation (TIALD) is a long non-coding RNA that physically interacts with the oncoprotein Aurora kinase A (AURKA), promoting its degradation via the lysosomal pathway. TIALD expression is regulated by the m6A RNA methyltransferase METTL16: m6A-mediated methylation by METTL16 decreases TIALD stability and abundance in hepatocellular carcinoma. Loss of TIALD leads to increased AURKA levels, driving epithelial-mesenchymal transition (EMT), metastasis, and poor clinical outcomes. In HCC, TIALD has shown potential as both a prognostic biomarker and a therapeutic modulator: tumors with low TIALD expression may be more sensitive to the AURKA inhibitor alisertib. TIALD illustrates the emerging role of lncRNAs in regulating non-proteasomal protein degradation and cancer biology.
- Other names
- AC079360.1transcript that induced AURKA lysosomal degradationTIALD
02
Mechanism of action
Drugs targeting this pathway (like alisertib) block AURKA kinase activity; indirectly, TIALD enhances efficacy by promoting AURKA degradation
03
Biological functions
Regulation of protein degradation (specifically AURKA via the lysosomal pathway)Inhibition of metastasis (in hepatocellular carcinoma)Negative regulation of EMT (epithelial-mesenchymal transition)Putative involvement in cell proliferation and apoptosis (by modulating AURKA)
04
Disease associations
Cancer (primarily hepatocellular carcinoma)Metastasis suppressionPrognosis marker (low expression is correlated with poor outcome in HCC)
05
Safety considerations
Null (no specific safety concerns or therapeutic challenges related directly to TIALD reported in available sources; as a non-coding RNA, major therapeutic concern would be deliverability and specificity for gene therapy approaches)
06
Interacting drugs
Alisertib
07
Biomarkers
TIALD expression level (as a prognostic biomarker for HCC progression and therapeutic response to AURKA inhibitors)
Beyond the preview
Go deeper on Transcript inducer of AURKA lysosomal degradation (TIALD).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Transcript inducer of AURKA lysosomal degradation (TIALD).